X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3668) 3668
Newsletter (196) 196
Newspaper Article (45) 45
Book Chapter (24) 24
Magazine Article (12) 12
Dissertation (4) 4
Book / eBook (2) 2
Conference Proceeding (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2558) 2558
hiv (1684) 1684
animals (1329) 1329
index medicus (1303) 1303
hiv-1 - immunology (1202) 1202
immunology (1164) 1164
virology (1109) 1109
viruses (964) 964
human immunodeficiency virus--hiv (876) 876
human-immunodeficiency-virus (809) 809
molecular sequence data (746) 746
infectious diseases (738) 738
aids (727) 727
hiv infections - immunology (698) 698
amino acid sequence (697) 697
hiv-1 - genetics (680) 680
research (653) 653
virus diseases (653) 653
vaccines (647) 647
hiv-1 (607) 607
aids vaccines - immunology (600) 600
proteins (599) 599
female (573) 573
antibodies (561) 561
immunodeficiency-virus type-1 (557) 557
infection (552) 552
hiv envelope protein gp120 - immunology (551) 551
hiv envelope protein gp160 (542) 542
cell line (534) 534
mice (530) 530
infections (499) 499
research article (483) 483
aids vaccines (480) 480
human immunodeficiency virus (480) 480
health aspects (472) 472
acquired immune deficiency syndrome--aids (471) 471
hiv antibodies - immunology (466) 466
hiv infection (437) 437
immunization (427) 427
hiv infections - virology (419) 419
gene products, env - immunology (406) 406
multidisciplinary sciences (398) 398
envelope glycoprotein (390) 390
hiv-1 - physiology (375) 375
microbiology (371) 371
male (365) 365
neutralization tests (356) 356
gp120 (355) 355
glycoproteins (353) 353
vaccination (352) 352
hiv envelope protein gp120 - genetics (348) 348
hiv-1 - metabolism (346) 346
hiv envelope protein gp160 - immunology (333) 333
hiv envelope protein gp120 - metabolism (332) 332
hiv infections - prevention & control (329) 329
biochemistry & molecular biology (324) 324
medicine (319) 319
neutralizing antibodies (318) 318
antigens (317) 317
protein precursors - immunology (314) 314
analysis (309) 309
medicine, research & experimental (299) 299
acquired immune deficiency syndrome (297) 297
adult (284) 284
hiv antibodies - blood (284) 284
biology (281) 281
physiological aspects (280) 280
mice, inbred balb c (279) 279
medical research (277) 277
type-1 (266) 266
immune response (264) 264
science (263) 263
peptides (257) 257
enzyme-linked immunosorbent assay (255) 255
vaccine (254) 254
binding sites (250) 250
lymphocytes (249) 249
immunoglobulins (248) 248
t cells (244) 244
hiv envelope protein gp120 - chemistry (240) 240
epitopes (235) 235
mutation (233) 233
antibodies, neutralizing - immunology (230) 230
monoclonal-antibodies (230) 230
epitopes - immunology (226) 226
neutralization (226) 226
protein (226) 226
hiv envelope protein gp41 - immunology (225) 225
cd4 antigens - metabolism (221) 221
hiv envelope protein gp160 - genetics (221) 221
cell biology (214) 214
hiv antigens - immunology (214) 214
hiv-1 - drug effects (212) 212
t-lymphocytes, cytotoxic - immunology (211) 211
immunogenicity (206) 206
aids vaccines - administration & dosage (205) 205
genetic aspects (204) 204
immune-responses (203) 203
vaccines, synthetic - immunology (202) 202
cells, cultured (199) 199
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3934) 3934
Japanese (12) 12
Chinese (11) 11
German (4) 4
Russian (4) 4
French (3) 3
Spanish (2) 2
Afrikaans (1) 1
Dutch (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS computational biology, ISSN 1553-7358, 2019, Volume 15, Issue 4, pp. e1006952 - 35
...) varies with HIV-1 envelope (Env) amino acid (AA) sequence features. An exhaustive analysis that tests how PE depends on every AA feature with sufficient variation would have low statistical power... 
MONOCLONAL-ANTIBODY VRC01 | POINT MUTATION | CD4 BINDING-SITE | STRUCTURAL BASIS | GP41 | BIOCHEMICAL RESEARCH METHODS | MATHEMATICAL & COMPUTATIONAL BIOLOGY | IMMUNODEFICIENCY-VIRUS TYPE-1 | RESISTANCE | VACCINE EFFICACY | WEB SERVER | TRANSMEMBRANE PROTEIN | Amino Acid Sequence | Antibodies, Monoclonal - pharmacology | HIV Infections - virology | Humans | Broadly Neutralizing Antibodies | CD4 Antigens | Glycosylation | Antibodies, Monoclonal - genetics | Antibodies, Neutralizing - immunology | HIV-1 - immunology | HIV Antibodies - immunology | Computer Simulation | HIV Envelope Protein gp160 - genetics | Protein Binding | HIV Envelope Protein gp160 - immunology | Binding Sites | Antibodies, Monoclonal - immunology | Forecasting - methods | Infection | Prevention | Viral antibodies | Machine learning | Antibodies | Data mining | HIV (Viruses) | Health aspects | Genetic aspects | Nucleotide sequencing | Methods | DNA sequencing | Sieve analysis | Statistical analysis | AMP | Amino acid sequence | Regression analysis | CD4 antigen | Learning algorithms | Glycoprotein gp160 | Sensitivity | Algorithms | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Data sets | Predictions | Software | Mutation | Glycoprotein gp120 | Neutralization | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Journal of Virology, ISSN 0022-538X, 2017, Volume 91, Issue 3
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2013, Volume 8, Issue 10, p. e78521
.... We previously demonstrated the ability of Newcastle disease virus (NDV) as a vaccine vector to express oligomeric Env protein gp160 and induce potent humoral and mucosal immune responses... 
VACCINE DEVELOPMENT | NEUTRALIZING ANTIBODY-RESPONSE | IMMUNIZATION | PROTEIN | ELICITS | TRIMERS | MULTIDISCIPLINARY SCIENCES | MONOMERIC GP120 | TYPE-1 ENVELOPE GLYCOPROTEIN | FOREIGN GENE | IMMUNODEFICIENCY | HIV Envelope Protein gp120 - genetics | HIV Infections - prevention & control | env Gene Products, Human Immunodeficiency Virus - immunology | Humans | AIDS Vaccines - immunology | Immunity, Mucosal | Antibodies, Viral - blood | HIV Envelope Protein gp120 - immunology | HIV Infections - immunology | env Gene Products, Human Immunodeficiency Virus - genetics | Immunity, Humoral | Protein Engineering | HIV Envelope Protein gp160 - genetics | Female | Antibodies, Viral - biosynthesis | HIV Infections - blood | Protein Structure, Tertiary | Gene Expression | Guinea Pigs | HIV Infections - virology | Recombinant Proteins - genetics | HIV-1 - immunology | Animals | Recombinant Proteins - immunology | Antibodies, Neutralizing - biosynthesis | Newcastle disease virus - genetics | Vaccines, Attenuated | HIV Envelope Protein gp160 - immunology | Mice | Mice, Inbred BALB C | AIDS Vaccines - administration & dosage | Genetic Vectors | Antibodies, Neutralizing - blood | Oligomers | Newcastle disease | AIDS vaccines | Genetic vectors | Monoclonal antibodies | T cells | HIV (Viruses) | Epidemics | Veterinary colleges | Immunization | Mucosal immunity | CD8 antigen | Envelope protein | Viruses | Homology | Lymphocytes T | Vaccines | Immune response (humoral) | CD4 antigen | Proteins | Glycoprotein gp160 | Immunogenicity | Acquired immune deficiency syndrome--AIDS | Guinea pigs | Human immunodeficiency virus--HIV | Recombinants | Glycoprotein gp120 | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 535, Issue 7613, pp. 556 - 560
.... Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody against the CD4 binding site of the HIV-1 Env protein(1... 
RESPONSES | POTENT | REPLICATION | GENETIC-DETERMINANTS | IMMUNOTHERAPY | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | SEQUENCE | ANTIRETROVIRAL THERAPY | MONOCLONAL-ANTIBODIES | Anti-HIV Agents - pharmacology | Antibodies, Neutralizing - administration & dosage | Disease Reservoirs - virology | Humans | Middle Aged | Male | Proviruses - immunology | Anti-HIV Agents - administration & dosage | Tissue Distribution | Young Adult | Antibodies, Monoclonal, Humanized | HIV Infections - immunology | Proviruses - drug effects | Antibodies, Neutralizing - immunology | HIV-1 - growth & development | HIV Antibodies - immunology | HIV Envelope Protein gp160 - chemistry | Time Factors | Antibodies, Neutralizing - therapeutic use | Binding Sites - immunology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Binding Sites - drug effects | HIV Envelope Protein gp160 - metabolism | Drug Administration Schedule | HIV-1 - drug effects | HIV Infections - virology | Broadly Neutralizing Antibodies | HIV Antibodies - administration & dosage | Viral Load - immunology | Proviruses - growth & development | HIV-1 - immunology | HIV Envelope Protein gp160 - antagonists & inhibitors | Adolescent | HIV Infections - drug therapy | Aged | HIV Envelope Protein gp160 - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Prevention | Antiviral agents | HIV antibodies | Dosage and administration | Host-virus relationships | Drug therapy, Combination | Drug therapy | Health aspects | HIV infection | Methods | Clinical trials | Antiretroviral drugs | Immunoglobulins | Human immunodeficiency virus--HIV | Binding sites
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e113463
Journal Article
Journal of virology, ISSN 1098-5514, 2016, Volume 90, Issue 19, pp. 8842 - 8854
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 10, p. e0223844
To develop an effective therapeutic vaccine against HIV-1, prediction of the most conserved epitopes derived from major proteins using bioinformatics tools is an alternative achievement... 
SYSTEM | IN-VIVO DELIVERY | IMMUNOGENICITY | GENE | IMMUNE-RESPONSES | MULTIDISCIPLINARY SCIENCES | DNA-VACCINE | IDENTIFICATION | NUCLEIC-ACIDS | EPITOPES | ANTIGEN | Amino Acid Sequence | HIV Core Protein p24 - immunology | Human Immunodeficiency Virus Proteins - immunology | Humans | Viral Regulatory and Accessory Proteins - metabolism | Epitopes, T-Lymphocyte - chemistry | Human Immunodeficiency Virus Proteins - metabolism | vif Gene Products, Human Immunodeficiency Virus - metabolism | HIV-1 - immunology | nef Gene Products, Human Immunodeficiency Virus - immunology | HEK293 Cells | HIV Envelope Protein gp160 - immunology | Epitopes, T-Lymphocyte - immunology | Epitopes, T-Lymphocyte - metabolism | Cell-Penetrating Peptides - metabolism | Prevention | Care and treatment | AIDS vaccines | Usage | Diagnosis | Scanning electron microscopes | HIV infection | Risk factors | Computational biology | Biotechnology | Flow cytometry | Peptides | Toxicity | Viruses | Vaccines | Allergenicity | Epidemiology | Mammalian cells | Nanoparticles | Proteins | Hepatitis | Transfection | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Bioinformatics | Deoxyribonucleic acid--DNA | Binding | Scanning electron microscopy | Antigens | Immune response | Quantum dots | Epitopes | Glycoprotein gp160 | Major histocompatibility complex | Nef protein | Immunogenicity | Pharmacy | Cell lines | Affinity | Viral infections | Acquired immune deficiency syndrome | Deoxyribonucleic acid | Recombinant | AIDS | HIV | DNA | Human immunodeficiency virus
Journal Article